Hudson, Liam http://orcid.org/0009-0000-8844-0059
Mason, Jeremy W.
Westphal, Matthias V. http://orcid.org/0000-0003-0693-0789
Richter, Matthieu J. R.
Thielman, Jonathan R. http://orcid.org/0000-0002-8677-5071
Hua, Bruce K. http://orcid.org/0000-0002-7330-2312
Gerry, Christopher J. http://orcid.org/0000-0002-7602-0492
Xia, Guoqin http://orcid.org/0000-0001-7666-9550
Osswald, Heather L.
Knapp, John M.
Tan, Zher Yin
Kokkonda, Praveen
Tresco, Ben I. C.
Liu, Shuang http://orcid.org/0000-0003-3287-2404
Reidenbach, Andrew G.
Lim, Katherine S. http://orcid.org/0000-0003-0391-6877
Poirier, Jennifer
Capece, John
Bonazzi, Simone
Gampe, Christian M.
Smith, Nichola J. http://orcid.org/0000-0002-3799-0074
Bradner, James E. http://orcid.org/0000-0002-2718-4415
Coley, Connor W. http://orcid.org/0000-0002-8271-8723
Clemons, Paul A. http://orcid.org/0000-0002-1800-5112
Melillo, Bruno http://orcid.org/0000-0002-9708-5287
Hon, C. Suk-Yee
Ottl, Johannes
Dumelin, Christoph E.
Schaefer, Jonas V. http://orcid.org/0000-0002-8332-4371
Faust, Ann Marie E. http://orcid.org/0000-0002-7468-5984
Berst, Frédéric
Schreiber, Stuart L. http://orcid.org/0000-0003-1922-7558
Zécri, Frédéric J. http://orcid.org/0000-0002-2469-8875
Briner, Karin
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM127045)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA217848, U01CA272612)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 25 October 2022
Accepted: 31 July 2023
First Online: 15 August 2023
Change Date: 21 November 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-43518-2
Competing interests
: C.J.G. is a shareholder in and employee of Kisbee Therapeutics. C.W.C. is an advisor to Anagenex. P.A.C. is an advisor to nference, Inc., Pfizer, Inc., and Belharra Therapeutics. B.M. is a scientific advisor to Magnet Biomedicine. S.L.S. is a shareholder and serves on the Board of Directors of Jnana Therapeutics and Kojin Therapeutics; is a shareholder and advises Kisbee Therapeutics, Belharra Therapeutics, Magnet Biomedicine, Exo Therapeutics, and Eikonizo Therapeutics; advises Vividian Therapeutics, Eisai Co., Ltd., Ono Pharma Foundation, F-Prime Capital Partners, and the Genomics Institute of the Novartis Research Foundation; and is a Novartis Faculty Scholar. All other authors declare no competing interests.